Download Free Medical Malignant Lesions of the Larynx PowerPoint Presentation

Malignant Lesions of the Larynx PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : Check out this medical presentation on Ear, Nose, and Throat Facts, which is titled "Malignant Lesions of the Larynx", to know about the malignant lesions of the larynx.

Tags : Ear, Nose, Throat Facts, Malignant Lesions, Larynx

Published on : Jul 10, 2021 | Views : 2195 | Downloads : 2

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

Malignant Lesions of the Larynx Renee Penn M.D. Head & Neck Oncology Fellow Division of Head and Neck Surgery University of California, Los Angeles
Slide 2-

Incidence 10K new cases of laryngeal cancer in U.S. annually 3,900 deaths annually Gender Since 1950- M:F ratio 15:1 5:1 in 2004 women have equal place in the toxic work environment cigarette smoking Risk factors: Tobacco 13-fold risk for laryngeal cancer for smokers risk increases with increasing tobacco use Alcohol 34-fold risk for laryngeal cancer if consume >1.5 L wine/day Tea time? mate in Latin America and chimarra in Brazil
Slide 3-

Decreasing Survival Among Patients with Laryngeal Cancer NCDB analysis: mid-1980s to mid-1990s. Increased chemo-radiation, decreased open surgery, increased endoscopic resection The most notable decline in the 5-year relative survival: advanced-stage glottic cancer early-stage supraglottic cancers “The decreased survival recorded for patients with laryngeal cancer in the mid-1990s may be related to changes in patterns of management.” Hoffman et al. Laryngeal cancer in the United States: changes in demographics, patterns of care, and survival. Laryngoscope. 2006 Sep;116(9 Pt 2 Suppl 111):1-13.
Slide 4-

Genetics/ Risk factors Aneuploidy Tumor suppressor gene inactivation Gene locus 17p13 : mutant p53 ………………………….DNA repair, apoptosis Gene locus 9p21 : mutant p16 …………………………. Cell cycle regulation Proto-oncogene activation Proto-oncogene (11q13) amplifies cyclin D1………. Cell cycle regulation Mutagen-induced chromosome breaks HPV Types 16 and 18: E6 and E7 viral protein-mediated degradation of p53 Oropharyngeal malignancy GERD Koufman: n=31 with glottic SCC, GERD documented in 84%; only 58% were smokers
Slide 5-

Embryology Frazer (1909) supraglottis originates from the buccopharyngeal primordium high risk of bilateral neck disease vs. glottic tumors - metastasize ipsilaterally Pressman (1956) separate derivation from glottis- supraglottic tumors of substantial bulk do not spread across the laryngeal ventricle to the vocal cord Tucker and Smith (1982) Dye studies anatomically based confirmation re: elastic tissue barriers Formed basis of partial laryngeal surgery Already advocated by Biller Cummings: otolaryngology, 4th ed- 2005 - Mosby, Inc.
Slide 6-

Anatomy Fibroelastic membranes Barriers to carcinoma spread Quadrangular membrane Superior free edge= AE fold Inferior free edge= False cord Conus elasticus Supports vocal fold Lateral attachment at cricoid Medial attachment at anterior thyroid cartilage Free edge forms vocal ligament Cummings: otolaryngology, 4th ed- 2005 - Mosby, Inc.
Slide 7-

Pre-epiglottic space & Para-glottic space Pre-epiglottic space Anterior: thyrohyoid membrane & thyroid cartilage Posterior: epiglottis elastic cartilage Inferior: Petiole attachment to thyroid cartilage Conduit : elastic epiglottic cartilage has perforations -direct extension of infrahyoid supraglottic cancer into this fascia-bound space Bilateral neck drainage Paraglottic space quadrangular membrane inferiorly conus elasticus anteriorly and medially thyroid cartilage laterally Myers: Laryngoscope, Volume 106(5).May 1996.559-567 Cummings: otolaryngology, 4th ed- 2005 - Mosby, Inc.
Slide 8-

Transglottic tumors Usually initiate as supraglottic or glottic cancers McGravan (1961) must cross three regions: false cords, ventricle, true cord alters prognosis Fail the compartmentalization hypothesis direct mucosal extension paraglottic space McGavran et al. Cancer 1961.
Slide 9-

Diagnosis Dysphagia Vocal changes Aspiration Otalgia Blood-tinged sputum Neck mass Cachexia Dyspnea Pain Halitosis
Slide 10-

Natural History WITHOUT Treatment Hemoptysis> supraglottic tumors Dysphonia> TVC/glottic lesions Airway Obstruction> insidious subglottic tumors Aspiration> supraglottic (also with incompetent glottis) Otalgia> supraglottic (infiltration of musculature) Dysphagia: any location, muscle, sensory, motor, joint
Slide 11-

Histology >95% SCC Variations : verrucous carcinoma, spindle cell carcinoma, basaloid SCC, and papillary SCC Other types of carcinoma: neuroendocrine carcinoma lymphepitheliomatous carcinoma adenocarcinoma others (sarcomas, lymphomas) adenoid cystic (trachea more than subglottis) Underlying: hyperplasia, dysplasia, CIS Overlying: surface keratinization may be present.
Slide 12-

Histology Mucosa: 5-7 cell layers stratified squamous epithelium, (eg, ventricle, false cord, and subglottis) Mitotic figures: present in the basal layer should be absent above this second layer CIS: full-thickness atypia of the squamous cells Atypia is characterized by the cell architecture: mitoses count per hpf, high NC ratio, large nucleoli Differentiation is characterizes by the tissue architecture: well, moderately, or poorly differentiated
Slide 13-

Whatcha got??? Patients with glottic tumors are seen early because of hoarseness…. Biopsy !!!!! Oops! fungal laryngitis, sarcoidosis, tuberculosis, or Wegener's granulomatosis , pseudoepitheliomatous hyperplasia (granular cell myoblastoma) The five categories of laryngeal squamous cell abnormality (from benign to clearly malignant): hyperkeratosis hyperkeratosis with atypia carcinoma in situ (CIS) superficially invasive carcinoma invasive carcinoma
Slide 14-

H, H+A, CIS hyperkeratosis +/- atypia and CIS conservative management: stripping of VC 5%–30% with future invasive cancer follow-up and possible re-biopsy 6 - 12 weeks
Slide 15-

Superficially invasive vs. Invasive SCC Why care? Cummings: otolaryngology, 4th ed- 2005 - Mosby, Inc.
Slide 16-

Superficial vs. Invasive Glottic SCC Superficial invasive carcinoma vs. CIS It is all about the SLP!!!!! “The central third” early symptoms of voice change Sampling error: Slaughter's hypothesis of field cancerization as described originally for the oral cavity (1946)
Slide 17-

Management of precancerous lesions Radiotherapy …not so much!!! failure (10%) no future option for XRT T1 / T2 Surgery Generous stripping Informed consent re: multiple treatments Good compliance (years) Supravital staining with toluidine blue Rapid or frequent recurrence Smoking cessation program must be part of management!!!!
Slide 18-

Peeps you know… things you should know… Blackwell KE, Calcaterra TC, Fu YS. Laryngeal dysplasia: epidemiology and treatment outcome. Ann Otol Rhinol Laryngol. 1995 Aug;104(8):596-602. Retrospective (n=65) long-term follow-up for laryngeal squamous dysplasia Results: 33 patients demonstrating moderate dysplasia, severe dysplasia, or carcinoma in situ Invasive carcinoma developed in… 10 of 21 patients (48%) treated endoscopically all salvaged!!!!! 0 of 12 patients treated by more aggressive Tx (EBRT, partial laryngectomy, or TL) Laryngeal preservation 15 of 21 patients (71%) in the endoscopic treatment group 11 of 12 patients (92%) in the aggressive treatment group ……..(not statistically significant) “We conclude that there is a moderately high rate of progression to invasive carcinoma…. However, with close, long-term follow-up, patients undergoing endoscopic therapy have an overall outcome similar to that in patients treated with partial laryngectomy or radiotherapy prior to developing invasive disease.”
Slide 19-

Radiology Tumor extent (limitations of endoscopy) Pre-epiglottic space and paraglottic space involvement, cartilage erosion MRI: high-density tumor vs fat in the preepiglottic space Soft tissue invasion Nodal disease ECS CT: thyroid cartilage destruction (presence mandates a total laryngectomy) Still undercalls cartilage invasion
Slide 20-

Early Glottic Cancer (T1/T2) Less biologically aggressive than supraglottic or hypopharyngeal well to moderately differentiated remains localized to the glottic compartment longer without neck or distant metastases: sparse submucosal lymphatics Symptoms present early most tumors originate on the free surface of the true vocal fold anterior two-thirds - hoarseness invites medical evaluation Treatment radiotherapy or conservation surgery no need for elective ND surgery offers 90% to 95% cure rates for T1 lesions***** surgical salvagetotal laryngectomy equal long-term cure but with different morbidities ***superstar status material
Slide 21-

Early Glottic Cancer: Effect of anatomy on management Radiation failure site: Sub-glottis , anterior commissure , and arytenoid involvement Middle third lesions Easiest to cure: respond well to XRT, endoscopic- laser resection, or open cordectomy Cure rates approach 100%; 95% cure rate for radiotherapy Anterior commissure Concerns regarding XRT: mixed reports for T1 lesions Cure- 50-92%
Slide 22-

Hemi-laryngectomy after XRT Failure Biller et al 1970: Lesion limited to one VC may involve the anterior commissure, but not contralateral VC Body of arytenoid free of tumor Sub-glottic extension <5 mm Mobile VC No cartilage invasion Recurrence correlating with initial tumor
Slide 23-

Sub-glottic SCC 1% of larynx cancers Clinical presentation: airway obstruction no response to management for COPD airway insufficiency & immediate relief when intubated Below conus elasticus (1 cm below free edge of the TVC) Local spread: cricoid cartilage and thyroid gland Lymphatic spread: Level IV nodes, Delphian node, and paratracheal nodes
Slide 24-

Management of Subglottic SCC Mandates TL laryngeal framework invasion is frequent Adjunct procedures: Ipsilateral thyroidectomy paratracheal ND Adjuvant XRT positive nodes extensive invasion ports must include the superior mediastinum Monitor for stomal recurrence
Slide 25-

…Bad juju… VC hypomobility reduces the cure rates advantage of surgery over radiation Arytenoid invasion High risk for post-op dysphagia in organ-sparing procedures
Slide 26-

What Our Veterans Have Taught Us Department of Veterans Affairs (VA) Laryngeal Cancer Study NEJM, 1991 Random assignment: Stage III & IV laryngeal SCC TL and adjuvant XRT Induction chemoTx with cisplatin and fluorouracil, followed by XRT (if +response to induction chemotherapy) Salvage TL If no response to chemoTx Residual/ recurrent disease after above 2 Results 2 year survival rate in first 2 groups (non-salvage groups) was 68 % laryngeal preservation: possible in 64 % of induction chemotherapy (41% overall) “The efficacy of chemotherapy followed by radiotherapy (with surgical salvage) was similar to that of surgery followed by radiotherapy and offered the added benefit of laryngeal preservation in two thirds of the patients treated by this approach. “
Slide 27-

RTOG (Radiation Therapy Oncology Group) NEJM, 2003 Stage III & IV laryngeal SCC* Premise: XRT alone survival and laryngeal preservation similar to those achieved in the VA study (*ie. We don’t need no stinkin’ chemo….) Induction chemoTx followed by XRT Concurrent chemoXRt XRT alone *patients with large, T4 lesions (tumors extending through the thyroid cartilage or into the base of the tongue) were excluded Results: 2 and 5 year survival rates were similar among the three groups concurrent chemotherapy : higher rates of laryngeal preservation and local control acute toxic effects were higher in both chemotherapy groups than in the XRT group late toxic effects, including swallowing dysfunction, were similar in all three groups
Slide 28-

RTOG (Radiation Therapy Oncology Group) “These data confirm that initial treatment aimed at laryngeal preservation is a realistic and feasible option for most patients with intermediate- or late-stage laryngeal cancer. The outcome in patients able to tolerate chemotherapy will be best with concurrent chemotherapy and radiotherapy. The use of induction chemotherapy followed by radiotherapy is not supported by the results of this trial, and patients unable to tolerate concomitant chemotherapy and radiotherapy should receive radiotherapy alone.”
Slide 29-

“Often cancer seems to have limits, while the surgeon seems to have none… We should make efforts to force upon our knife the same limits as those which surrounding tissues or structures force upon cancer and its spread.“ …Partial laryngeal surgery… Bocca et al. Extended supraglottic laryngectomy. Review of 84 cases. Ann Otol Rhinol Laryngol 1987; 96:384. Ouch!!!!
Slide 30-

Supraglottic SCC Amenable to organ-sparing partial laryngectomy Endoscopic: Early supraglottic tumors(suprahyoid) electrocautery or by carbon dioxide laser best for suprahyoid lesions: no invasion of pre-epiglottic space infrahyoid tumors – not so much! What hasn’t changed… Cervical metastasis Bilateral
Slide 31-

TLM (Transoral laser microsurgery) Prospective , multi-center TLM in 117 patients T2 to T4 lesions, stage III or stage IV, glottic or supraglottic SCC ND (91 patients), and adjuvant radiotherapy (45 patients) Outcomes- 5-year estimates: local control (74%), locoregional control (68%), disease-free survival (58%), overall survival (55%), distant metastases (14%) ...similar to other modalities… QOL? 2 patients (3%) were tracheotomy dependent 4 patients (7%) were feeding tube dependent Hinni et al. Transoral Laser Microsurgery for Advanced Laryngeal Cancer. Arch Otolaryngol Head Neck Surg. 2007;133(12):1198-1204.
Slide 32-

U wit me??? “Eligibility criteria for TLM are broad… Contraindications: inadequate endoscopic access, extension of tumor to involve the great vessels of the neck, marked extension of the primary tumor and the nodal disease merged or encased around the great vessels, and tumor extension which would put the patient at risk for aspiration (ie, bilateral arytenoid invasion)... Unlike chemo and XRT, select patients with large-volume T4 tumors are eligible for TLM… (would you do this to your mother??) In addition, no rigid age-related, hematological, biochemical, or performance status criteria preclude patients from TLM surgery.” Hinni et al. Transoral Laser Microsurgery for Advanced Laryngeal Cancer. Arch Otolaryngol Head Neck Surg. 2007;133(12):1198-1204.
Slide 33-

No they diin’t!! RTOG trial: Given comparable survival outcomes b/wn surgery and organ sparing Tx the logical preference must be for a nonsurgical organ-preserving approach. Hinni et al: “This view largely ignored the established role of current open partial laryngectomy techniques and a growing expertise with organ-preserving TLM in Europe and North America. In responding to this contention….The data presented herein can specifically compare the outcomes of TLM with or without adjuvant RT to the RTOG Trial data.” Hinni et al. Transoral Laser Microsurgery for Advanced Laryngeal Cancer. Arch Otolaryngol Head Neck Surg. 2007;133(12):1198-1204.
Slide 34-

Double-Edged Sword? Or Can’t Go Wrong? XRT worse than laryngeal preservation? ….But both are organ sparing…..
Slide 35-

Conservation Laryngeal Surgery – All Comers Vertical Partial Laryngectomies Vertical Hemilaryngectomy Frontolateral vertical hemilaryngectomy. Posterolateral vertical hemilaryngectomy Extended vertical hemilaryngectomy Epiglottic Laryngoplasty Horizontal Partial Laryngectomies Supraglottic laryngectomy Supracricoid Partial Laryngectomy w/ Cricohyoido-Epiglottopexy
Slide 36-

Supraglottic Laryngectomy Patient selection younger vigorous strong motivation good pulmonary reserve Must tolerate the mild-to-moderate aspiration COPD (may nix the deal) Even with gastrostomy -salivary aspiration may be over-whelming
Slide 37-

Issues after Supraglottic Laryngectomy…. Vocal quality Better than TEP? Predictors of success? Wound healing /stabilization irradiation Prolonged NGT / PEG use extent of removal of the arytenoid asymmetric removal of the false cords remember: at least one SLN is resected resection of hyoid & BOT may NOT be related to swallowing outcome
Slide 38-

Limitations to Supraglottic Laryngectomy Failed full-course radiation for supraglottic lesions increased risk because of unrecognized submucosal tumor spread original tumor configuration vs . recurrent tumor dimensions Thyroid cartilage invasion or anterior commissure involvement tumor has broken the anterior inner perichondrial sheath standard cartilage cuts for partial surgery are high risk Cricoid cartilage involvement severe dysphagia- laryngeal preservation bilateral arytenoid involvement: absolute contraindication (Biller)
Slide 39-

Nodal Metastasis in Supraglottic SCC: Outcomes Snyderman et al: decreased survival in patients with ECS within NM Myers et al: Nodal metastasis 84% of patients without NM survived at least 2 years vs. 46% of patients with NM survived 2 years Of patients w/ recurrence in the neck, 9 (64%) had ECS 71% who developed distant metastasis had histologic evidence of ECS Myers et al. Management of carcinoma of the supraglottic larynx: evolution, current concepts and future trends. Laryngoscope 1996; 106:559
Slide 40-

Supraglottic SCC and Survival Myers et al. Management of carcinoma of the supraglottic larynx: evolution, current concepts and future trends. Laryngoscope 1996; 106:559 Two-Year Survival Rates of Supraglottic Carcinoma by Stage
Slide 41-

Conclusions Progress? HPV? Anatomy (period!) Multi-disciplinary approach Early glottic SCC: Slaughter’s Hypothesis VA study RTOG TLM
Slide 42-

References Forastiere et al. Concurrent Chemotherapy and Radiotherapy for Organ Preservation in Advanced Laryngeal Cancer. NEJM. Volume 349: 2091-2098; 2003. The Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. NEJM. Volume 324:1685-1690, 1991. Bocca et al. Extended supraglottic laryngectomy. Review of 84 cases. Ann Otol Rhinol Laryngol 1987; 96:384. Hinni et al. Transoral Laser Microsurgery for Advanced Laryngeal Cancer. Arch Otolaryngol Head Neck Surg. 2007;133(12):1198-1204. Hoffman et al. Laryngeal cancer in the United States: changes in demographics, patterns of care, and survival. Laryngoscope. 2006 Sep;116(9 Pt 2 Suppl 111):1-13. Blackwell et al. Laryngeal dysplasia: epidemiology and treatment outcome. Ann Otol Rhinol Laryngol. 1995 Aug;104(8):596-602. Cummings: Otolaryngology, Head and Neck Surgery. 4th Ed- 2005 - Mosby, Inc. Philadelphia, Pennsylvania. Bailey’s: Head and Neck Surgery, Otolaryngology. 3rd Ed- 2005 –Lippincott, Williams & Wilkins, Inc. Philadelhpia, Pennsylvania. Biller et al. Hemilaryngectomy following radiation failure for carcinoma of the vocal cords. Laryngoscope. 80(2):249-53, 1970 Feb. Myers et al. Management of carcinoma of the supraglottic larynx: evolution, current concepts and future trends. Laryngoscope 1996; 106:559. Snyderman et al. Extracapsular spread of carcinoma in cervical lymph nodes: impact upon survival in patients with carcinoma of the supraglottic larynx. Cancer. 1985;56:1597-1599. McGavran et al. The incidence of cervical lymph node metastase from epidermoid carcinoma of the larynx and their relationship to certain characteristics of the primary tumor. Cancer 1961;14:55-66.